• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Exome Sequencing or Targeted Gene Panels for Detecting Nonimmune Hydrops Fetalis?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Next generation sequencing methods, such as targeted gene panels and exome sequencing, are increasingly used in prenatal diagnosis, but which is better at detecting abnormalities is unknown 
  • Norton et al. (AJOG, 2021) compared the diagnostic yield of exome sequencing vs gene panels in fetuses with nonimmune hydrops fetalis (NIHF) 

METHODS: 

  • Secondary analysis of a cohort study 
  • Population 
    • Pregnancies with features of NIHF 
  • Exposures 
    • Exome sequencing 
    • Simulated use of targeted gene panels for prenatal evaluation of NIHF or for specific disorders associated with NIHF 
  • Primary outcome 
    • Proportion of all genetic variants discovered through exome sequencing that would have been identified if a targeted gene panel had been used instead 
  • Secondary outcomes 
    • Proportion of genetic variants that would have been identified stratified by type of targeted gene panel  
      • e.g general NIHF, RASopathy, or metabolic 
    • Percent of variants of uncertain significance that would have been identified on the panels, assuming 100% analytical sensitivity and specificity of panels for variants in the included genes 

RESULTS: 

  • 127 pregnancies 
  • Exome sequencing  
    • Pathogenic or likely pathogenic variant: 29% of cases in a total of 29 genes 
    • Variant of uncertain significance with strong suspicion for clinical relevance: 9% of cases 
  • Panels offered 
    • Median number of genes offered with targeted NIHF commercial gene panels: 22 (range 11 to 148) 
  • Had a targeted gene panel been used instead of exome sequencing 
    • 45 to 52% of the 29 genes identified in NIHF exome cohort would have been sequenced 
    • 51 to 62% of the pathogenic variants would have been detected 
  • The largest NIHF targeted gene panel would have had a diagnostic yield of 18% as compared to 29% with exome sequencing 
  • The exome sequencing platform provided coverage for all of the exons on the commercial targeted gene panels 

CONCLUSION: 

  • Prenatal exome sequencing performed better than simulated targeted gene panel testing for nonimmune hydrops fetalis 
  • The authors suggest that for detecting genetically heterogeneous disorders, exome sequencing is superior to targeted gene panels 

Learn More – Primary Sources: 

Exome sequencing versus targeted gene panels for the evaluation of nonimmune hydrops fetalis 

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Single Gene vs Multigene Panel Testing for Cancer Predisposition: Are Guidelines Too Restrictive?
The Exome and Exome Sequencing: Prenatal Testing Recommendations
Can Whole-Exome Sequencing Help Diagnose Otherwise Unexplained Fetal Structural Anomalies?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site